Posts

Novo CEO Says Obesity Market Won’t Be Winner-Take-All With Lilly

on
Novo Nordisk CEO Mike Doustdar says the obesity drug market will not be a winner-take-all battle with rival Eli Lilly, emphasizing differentiation among treatments like pills and injectables. Doustdar argues investors underestimate demand for choice, citing multiple insulin brands as a model for future GLP-1 obesity drugs with varying benefits. The Wegovy pill currently holds about 90% of the oral GLP-1 market, giving Novo an edge over Lilly's Foundayo pill despite Lilly's strength in injectables like Zepbound. Analysts project the obesity drug market could exceed $100 billion by 2030, supporting Doustdar's view of room for multiple players amid intense competition. Sources: Novo CEO says obesity market won't be winner-take-all ... Obesity not a winner-takes-all game, Novo CEO says Novo Nordisk CEO Mike Doustdar said investors are ... Novo Nordisk A/S Health News | Today's Latest Stories Novo Nordisk CEO Doustdar says obesity drugs market won...

Zealand's royalty deal

on

Scarring and Autoimmune Diseases Biotech BirchBioMed Files for Direct Nasdaq Listing

on

Pilot Project Between BioCytics and LIDE Biotech to Advance Immune-Based Cancer Cell Therapies

on

Trump Signs Executive Order Overhauling Pediatric Vaccine Recommendations

on

Zealand Sells Rights to Takeda’s Blood Cancer Drug for $100M Ahead of FDA Approval Decision

on

PDS Halts Phase 3 Head and Neck Therapy to Focus on Colorectal Program

on

Neurocrine Stands By Vykat XR as Prader‑Willi Experts Raise Safety Flags

on

PTC Therapeutics and Lilly Acquire Sangamo Assets in Bankruptcy Auction

on

Innovaccer in the News: $250M Funding Talks and AI Expansion

on

Trump signs executive order to overhaul pediatric vaccine recommendations

on

AbCellera, Silence Therapeutics, and InduPro Raise Significant Funding

on

Boulevard Bio launches with $65M to target IgAN and other autoimmune diseases with quarterly‑dosed BAFF/APRIL bispecific against Vera's Trutakna

on